ONL Therapeutics, Inc.

About ONL Therapeutics, Inc.

ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to protecting and improving the vision of patients with retinal disease. By advancing a breakthrough technology designed to protect key retinal cells from Fas-mediated cell death, ONL is pioneering a new approach to preserving vision. ONL is developing a platform of products for use in a wide range of blinding diseases, including retinal detachment, glaucoma, AMD and IRD.

What differentiates you from the competition?

ONL Therapeutics (ONL) developing a first-in-class treatment to protect and improve the vision of patients with retinal disease.

What are your top selling services or products that your company offers?

We do not sell products at this time. We are clinical stage biotech company with products in development and not yet approved for commercial sale.

If you had one message to get across to future customers, what would it be?

Get ready for a breakthrough therapy to protect the vision of your patients

What is the biggest marketing challenge that you will face in the upcoming year?

Fully enroll a global Phase 2 study in Dry age related macular degeneration